Asia Pacific Congenital Heart Diseases Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
1.39 Billion
USD
2.63 Billion
2025
2033
 Período de previsão |
2026 –2033 |
 Tamanho do mercado (ano base ) | USD 1.39 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 2.63 Billion |
 CAGR |
% |
| Principais participantes do mercado |
|
Mercado de Cardiopatias Congênitas na Ásia-Pacífico, por Tipo de Produto (Tratamento e Diagnóstico), Tipo de Doença (Cardiopatia Congênita Acianótica, Cardiopatia Congênita Cianótica e Cardiopatias Congênitas Complexas), Faixa Etária (Adultos com Cardiopatia Congênita, Recém-nascidos e Lactentes (0-1 ano), Crianças (1-12 anos) e Adolescentes (13-18 anos)), Usuário Final (Hospitais, Centros Cardíacos Pediátricos, Clínicas Especializadas, Laboratórios de Diagnóstico, Institutos de Pesquisa e Acadêmicos, Atendimento Domiciliar e Outros Usuários Finais), Canal de Distribuição (Licitação Direta, Distribuidores Atacadistas, Vendas no Varejo, Vendas Online e Outros) - Tendências e Previsões do Setor até 2033
Tamanho do mercado de cardiopatias congênitas na região Ásia-Pacífico
- O mercado de cardiopatias congênitas na região Ásia-Pacífico foi avaliado em US$ 1,39 bilhão em 2025 e deverá atingir US$ 2,63 bilhões em 2033 , com uma taxa de crescimento anual composta (CAGR) de 8,4% durante o período de previsão.
- A cardiopatia congênita (CC) refere-se a anormalidades estruturais ou funcionais do coração presentes ao nascimento, que podem afetar o fluxo sanguíneo, a oxigenação e a função cardiovascular em geral. O manejo da CC envolve tanto tratamento (intervenções cirúrgicas, procedimentos por cateter e terapias farmacológicas) quanto métodos diagnósticos (exames de imagem, ecocardiografia e testes genéticos) para detectar, monitorar e corrigir essas anormalidades.
- A cardiopatia congênita (CC) abrange um espectro de condições, incluindo cardiopatia congênita acianótica, cardiopatia congênita cianótica e cardiopatias congênitas complexas, afetando pacientes de todas as faixas etárias, desde neonatos e lactentes até crianças, adolescentes e adultos.
Análise do Mercado de Cardiopatias Congênitas na Região Ásia-Pacífico
- O mercado de cardiopatias congênitas na região Ásia-Pacífico está apresentando crescimento constante, impulsionado pela crescente prevalência de defeitos cardíacos congênitos, pela adoção cada vez maior de procedimentos cardíacos minimamente invasivos e pela crescente conscientização sobre a importância do diagnóstico precoce e da intervenção oportuna.
- Os sistemas de saúde em toda a região estão passando por uma modernização contínua, com investimentos públicos e privados focados na expansão de unidades de atendimento pediátrico e cardíaco, na melhoria dos resultados cirúrgicos e intervencionistas e na redução de complicações relacionadas a procedimentos. À medida que condições como cardiopatia congênita acianótica, cardiopatia congênita cianótica e cardiopatias congênitas complexas se tornam mais amplamente reconhecidas, a demanda por soluções eficazes de diagnóstico e tratamento aumentou, criando oportunidades de mercado sustentáveis.
- A China dominou o mercado de cardiopatias congênitas na região Ásia-Pacífico, com a maior participação na receita, de 34,11% em 2025, impulsionada por uma infraestrutura de saúde avançada, fortes investimentos governamentais e privados, alta adoção de tecnologias médicas inovadoras e ampla disponibilidade de equipamentos médicos especializados.
- Prevê-se que a Índia seja o país de crescimento mais rápido no mercado de cardiopatias congênitas da região Ásia-Pacífico durante o período de previsão, impulsionada pela crescente urbanização, aumento dos gastos com saúde, maior acesso a instalações de saúde modernas e crescente adoção de tecnologias médicas avançadas.
- O segmento de tratamento dominou a maior fatia da receita de mercado, com 65,95% em 2025, impulsionado pela crescente demanda por detecção precoce de doenças e monitoramento contínuo de pacientes em hospitais e clínicas.
Escopo do relatório e segmentação do mercado de cardiopatias congênitas na região Ásia-Pacífico
|
Atributos |
Principais informações sobre o mercado de cardiopatias congênitas na região Ásia-Pacífico |
|
Segmentos abrangidos |
|
|
Países abrangidos |
Ásia-Pacífico
|
|
Principais participantes do mercado |
|
|
Oportunidades de mercado |
|
|
Conjuntos de informações de dados de valor agregado |
Além das informações sobre cenários de mercado, como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e principais participantes, os relatórios de mercado elaborados pela Data Bridge Market Research também incluem análises aprofundadas de especialistas, epidemiologia de pacientes, análise de projetos em desenvolvimento, análise de preços e estrutura regulatória. |
Tendências do mercado de cardiopatias congênitas na região Ásia-Pacífico
“ Integração da Inteligência Artificial na Interpretação de Imagens e Estratificação de Risco ”
- A integração da inteligência artificial (IA) na interpretação de imagens e na estratificação de risco representa uma oportunidade de crescimento significativa para o mercado de cardiopatias congênitas na região Ásia-Pacífico, ao aprimorar a precisão diagnóstica, reduzir o tempo de interpretação e melhorar o suporte à decisão clínica em diversos contextos de saúde.
- Ferramentas baseadas em IA podem analisar imagens médicas — especialmente ecocardiogramas e exames cardíacos — com alta precisão, auxiliando os médicos na detecção de anormalidades estruturais sutis que poderiam passar despercebidas, e possibilitando o diagnóstico precoce e a avaliação de risco de cardiopatias congênitas (CC).
- À medida que as tecnologias de IA são cada vez mais validadas em pesquisas e testadas em programas clínicos, os sistemas de saúde pública da região podem se beneficiar de fluxos de trabalho mais eficientes, interpretação padronizada e do potencial de estender recursos avançados de diagnóstico a hospitais com poucos recursos e áreas rurais.
- Esses avanços não apenas melhoram os resultados para os pacientes, mas também apoiam uma adoção mais ampla de plataformas de imagem avançadas e modelos preditivos, fomentando assim a expansão do mercado de soluções de diagnóstico e estratificação de risco em toda a região da Ásia-Pacífico.
- Essas tendências tecnológicas apoiam a expansão dos serviços de diagnóstico e das soluções de avaliação de risco, fortalecendo o ecossistema de mercado geral para o tratamento de cardiopatias congênitas na região da Ásia-Pacífico.
Dinâmica do mercado de cardiopatias congênitas na região Ásia-Pacífico
Motorista
“Prevalência crescente de cardiopatias congênitas em recém-nascidos”
- O aumento da prevalência e das taxas de detecção de cardiopatias congênitas (CC) em recém-nascidos na região da Ásia-Pacífico são importantes impulsionadores do mercado para o ecossistema de doenças cardíacas congênitas.
- As cardiopatias congênitas estão entre as malformações congênitas mais comuns, e estudos regionais de saúde e programas de triagem em países populosos como China, Índia e Indonésia têm relatado um número substancial de casos e uma cobertura de detecção crescente nos últimos anos, refletindo uma demanda contínua por diagnósticos precoces, serviços especializados de cardiologia pediátrica, sistemas de ecocardiografia e soluções de tratamento intervencionista.
- A vigilância reforçada, os programas de triagem neonatal e as intervenções apoiadas pelo governo levaram a um maior número de casos identificados que necessitam de cuidados médicos e acompanhamento, expandindo as oportunidades de mercado para tecnologias de triagem, diagnóstico por imagem, cirurgia cardíaca pediátrica e soluções de gestão de pacientes a longo prazo em toda a região da Ásia-Pacífico.
- Além disso, o aumento dos investimentos governamentais em infraestrutura de saúde, a melhoria das políticas de reembolso e a adoção de sistemas hospitalares inteligentes estão acelerando ainda mais o mercado.
- Essas tendências são impulsionadas tanto por aumentos reais na incidência diagnosticada quanto por melhorias, promovidas por políticas públicas, na identificação de casos e nos registros de saúde neonatal.
- Em julho de 2025, o Tempo noticiou que o Ministro da Saúde da Indonésia afirmou que aproximadamente 12.000 bebês necessitam de cirurgia cardíaca congênita anualmente, mas apenas cerca de 6.000 a recebem, resultando em aproximadamente 6.000 mortes anuais por cardiopatias congênitas. Isso evidencia uma grande necessidade clínica não atendida de ampliação dos recursos para o tratamento cardíaco.
- O aumento documentado nos casos identificados de cardiopatia congênita e a expansão dos programas de triagem neonatal e diagnóstico em toda a região da Ásia-Pacífico ressaltam uma crescente carga de problemas de saúde na região, que alimenta diretamente a demanda por diagnósticos de cardiopatia congênita, ferramentas de intervenção e serviços de tratamento.
Restrição/Desafio
“ Alto custo do tratamento de cardiopatias congênitas ”
- O alto custo associado ao diagnóstico, intervenção cirúrgica, terapia com dispositivos e manejo a longo prazo de cardiopatias congênitas (CC) continua sendo um obstáculo significativo para o crescimento do mercado em toda a região da Ásia-Pacífico.
- O tratamento da cardiopatia congênita frequentemente requer cirurgias complexas de coração aberto, procedimentos intervencionistas avançados, internações hospitalares prolongadas e acompanhamento por toda a vida, o que impõe encargos financeiros substanciais às famílias e aos sistemas públicos de saúde.
- Em muitos países da região Ásia-Pacífico, a cobertura limitada de seguros de saúde, os gastos diretos com saúde e o acesso desigual a cuidados cardíacos pediátricos subsidiados restringem o tratamento oportuno, particularmente em populações de baixa e média renda.
- Mesmo onde existem programas públicos, a falta de financiamento, as longas listas de espera e os altos custos por procedimento limitam o volume de procedimentos realizados.
- Essas pressões de custos limitam a adoção de dispositivos e tecnologias avançadas, atrasam os percursos de tratamento e, em última análise, atuam como uma restrição estrutural à expansão do mercado de cardiopatias congênitas na região.
Escopo do mercado de cardiopatias congênitas na região Ásia-Pacífico
O mercado de cardiopatias congênitas na região Ásia-Pacífico está segmentado em cinco categorias principais com base no tipo de produto, tipo de doença, faixa etária, usuário final e canal de distribuição.
- Por tipo de produto
Com base no tipo de produto, o mercado de cardiopatias congênitas na região Ásia-Pacífico é segmentado em soluções de diagnóstico e tratamento. Em 2026, espera-se que o segmento de tratamento domine o mercado com uma participação de 66,05%, impulsionado pelo aumento da prevalência de doenças crônicas, pela demanda por terapias minimamente invasivas e pelos avanços em equipamentos terapêuticos personalizados, como stents cardiovasculares, implantes ortopédicos e sistemas de infusão.
Prevê-se que o segmento de tratamento apresente a taxa de crescimento anual composta (CAGR) mais rápida, de 8,5%, entre 2026 e 2033, impulsionado pelo crescente número de doenças crônicas e relacionadas ao estilo de vida, pela rápida adoção de intervenções minimamente invasivas e baseadas em cateteres e pela inovação tecnológica contínua em dispositivos implantáveis e de administração de medicamentos.
- Por tipo de doença
Com base no tipo de doença, o mercado de cardiopatias congênitas na região Ásia-Pacífico é segmentado em cardiopatia congênita acianótica, cardiopatia congênita cianótica e cardiopatias congênitas complexas. Em 2026, espera-se que o segmento de cardiopatia congênita acianótica domine o mercado de cardiopatias congênitas na região Ásia-Pacífico, com uma participação de 51,40%, impulsionado pela maior prevalência devido a fatores genéticos e ambientais, pela melhoria na triagem neonatal e nas capacidades de diagnóstico precoce, e pelo acesso crescente a tratamentos minimamente invasivos, como o fechamento transcateter de defeitos como comunicação interatrial (CIA) e comunicação interventricular (CIV).
Prevê-se que o segmento de cardiopatias congênitas complexas apresente a taxa de crescimento anual composta (CAGR) mais rápida, de 8,7%, entre 2026 e 2033, impulsionado pelos avanços em procedimentos cirúrgicos-intervencionistas híbridos, pelo aumento das taxas de sobrevivência de neonatos com condições graves como a síndrome da hipoplasia do ventrículo esquerdo (SHVE) e a tetralogia de Fallot, e pela crescente demanda por dispositivos especializados, como as válvulas Melody e os stents revestidos.
- Por faixa etária
Com base na faixa etária, o mercado de cardiopatias congênitas na região Ásia-Pacífico é segmentado em neonatos e lactentes (0 a 1 ano), crianças (1 a 12 anos), adolescentes (13 a 18 anos) e adultos com cardiopatia congênita. Em 2026, espera-se que o segmento de adultos com cardiopatia congênita domine o mercado de cardiopatias congênitas na região Ásia-Pacífico, com uma participação de 34,46%, impulsionado pela melhoria nas taxas de sobrevivência infantil, que levam a uma crescente população de sobreviventes adultos, pela maior conscientização sobre complicações ao longo da vida, como arritmias e insuficiência cardíaca, e pelo aumento da demanda por cuidados de acompanhamento especializados, como desfibriladores implantáveis e terapias para hipertensão pulmonar.
Prevê-se que o segmento de adultos com cardiopatia congênita apresente a taxa de crescimento anual composta (CAGR) mais rápida, de 8,8%, entre 2026 e 2033, impulsionado pela crescente população de sobreviventes a longo prazo devido a intervenções pediátricas aprimoradas, pelo aumento dos riscos de condições secundárias, como arritmias e hipertensão pulmonar, que exigem gerenciamento contínuo com dispositivos, e pela maior ênfase em programas multidisciplinares para cardiopatias congênitas em adultos, que oferecem terapias avançadas, como marca-passos sem eletrodos e intervenções na válvula tricúspide.
- Por usuário final
Com base no usuário final, o mercado é segmentado em hospitais, centros de cardiologia pediátrica, clínicas especializadas, laboratórios de diagnóstico, institutos de pesquisa e acadêmicos, atendimento domiciliar e outros usuários finais. Em 2026, espera-se que o segmento de hospitais domine o mercado de cardiopatias congênitas na região Ásia-Pacífico, com uma participação de 59,22%, impulsionado por sua infraestrutura avançada para cirurgias cardíacas complexas e cateterismos, pela concentração de cardiologistas pediátricos e adultos especializados e pelo amplo acesso a ferramentas de diagnóstico de ponta, como ecocardiografia 3D e imagens intraoperatórias.
Prevê-se que o segmento de centros de cardiologia pediátrica apresente a taxa de crescimento anual composta (CAGR) mais rápida, de 9,1%, entre 2026 e 2033, impulsionado pela rápida expansão de instalações especializadas em regiões de alta prevalência, como China e Índia, por iniciativas governamentais para modernizar a infraestrutura de cuidados neonatais e infantis e pela crescente demanda por centros dedicados equipados com laboratórios de cateterismo híbridos e programas de cardiologia fetal.
- Por canal de distribuição
Com base no canal de distribuição, o mercado é segmentado em licitação direta, vendas no varejo, vendas online, distribuidores atacadistas e outros. Em 2026, espera-se que o segmento de licitação direta domine o mercado de cardiopatias congênitas na região Ásia-Pacífico, com uma participação de 52,83%. Esse crescimento é impulsionado pela preferência de grandes hospitais e centros de cardiologia pediátrica por compras em grande escala de dispositivos de alto custo, como oclusores septais e stents, pela rigorosa padronização regulatória que garante qualidade e transparência de preços, e pelas compras centralizadas obrigatórias por lei em países como China e Índia, visando otimizar os orçamentos de saúde.
Espera-se que o segmento de vendas online apresente a taxa de crescimento anual composta (CAGR) mais rápida, de 8,8%, entre 2026 e 2033, impulsionado pela rápida digitalização das plataformas de aquisição de serviços de saúde na região Ásia-Pacífico, pela crescente adoção de portais de comércio eletrônico por clínicas privadas e hospitais de menor porte para dispositivos de cardiopatia congênita, como ferramentas de monitoramento e acessórios, e pela maior eficiência da cadeia de suprimentos, que oferece preços competitivos e entregas mais rápidas.
Análise Regional do Mercado de Cardiopatias Congênitas na Ásia-Pacífico
- A China dominou o mercado de cardiopatias congênitas na região Ásia-Pacífico, com a maior participação na receita, de 34,11% em 2025.
- Apoiada por infraestrutura de saúde avançada, fortes investimentos governamentais e privados, alta adoção de tecnologias médicas inovadoras e ampla disponibilidade de equipamentos médicos especializados, essa situação é impulsionada por um cenário de crescimento acelerado.
- A região beneficia-se de uma população com inclinação tecnológica, estruturas regulatórias robustas e sistemas de saúde bem estabelecidos, que, em conjunto, facilitam a adoção de dispositivos médicos avançados em hospitais, clínicas e centros de diagnóstico.
Análise do Mercado de Doenças Cardíacas Congênitas na China
Em 2025, a China representou a maior fatia da receita na América do Norte, impulsionada por sua enorme população, que resulta em alta prevalência de cardiopatias congênitas ao nascimento, investimentos governamentais significativos em infraestrutura cardíaca pediátrica, como a iniciativa Healthy China 2030, e rápida expansão de centros de tratamento avançados que realizam um grande volume de intervenções cirúrgicas e por cateter.
Análise do Mercado de Doenças Cardíacas Congênitas na Índia
Prevê-se que a Índia cresça a uma taxa composta de crescimento anual substancial durante todo o período de previsão, impulsionada pela sua população crescente e pelas taxas de incidência de cardiopatias congênitas em ascensão, por programas governamentais de saúde de grande escala, como o Ayushman Bharat, que melhoram o acesso a cirurgias cardíacas pediátricas, e por redes de hospitais privados em rápido crescimento, equipadas com laboratórios de cateterismo híbridos para reparos minimamente invasivos.
Análise do Mercado Japonês de Cardiopatias Congênitas
Prevê-se que o Japão cresça a uma taxa composta de crescimento anual (CAGR) notável durante o período de previsão, impulsionado pelo seu sistema de saúde avançado que oferece suporte ao acompanhamento vitalício de cardiopatias congênitas em adultos (ACHD), pelo envelhecimento da população de sobreviventes decorrente das altas taxas de sobrevivência pediátrica e pela forte cobertura do seguro saúde nacional para dispositivos inovadores, como válvulas de última geração e implantes de monitoramento. A liderança tecnológica em cirurgias robóticas para cardiopatias congênitas, a expansão de programas especializados para cardiopatias congênitas em adultos em centros urbanos e as políticas governamentais proativas de triagem aceleram ainda mais a expansão constante do mercado japonês no cenário de cardiopatias congênitas da região Ásia-Pacífico.
Participação de mercado de cardiopatias congênitas na região Ásia-Pacífico
O setor de cardiopatias congênitas na região Ásia-Pacífico é liderado principalmente por empresas consolidadas, incluindo:
- Medtronic (EUA)
- Edwards Lifesciences Corporation (EUA)
- Laboratórios Abbott (EUA)
- Boston Scientific Corporation (EUA)
- Corporação Terumo (Japão)
- Siemens Healthineers (Alemanha)
- Philips Healthcare (Países Baixos)
- GE Healthcare (EUA)
- Lepu Medical Technology (China)
- Meril Life Sciences Pvt. Ltd. (Índia)
- Narang Medical Limited (Índia)
- Advacare Pharma (Índia)
- Corporação Científica Microport de Xangai (China)
- WL Gore & Associates, Inc. (EUA)
- B. Braun SE (Alemanha)
- LivaNova PLC (Reino Unido)
- OsCOR Inc. (EUA)
- LifeTech Scientific (China)
- Artivion (anteriormente CryoLife) (EUA)
- Pfizer Inc. (EUA)
- AstraZeneca PLC (Reino Unido)
- Bristol-Myers Squibb (BMS) (EUA)
- Sun Pharmaceutical Industries Ltd. (Índia)
- Novartis AG (Suíça)
Últimos desenvolvimentos no mercado de cardiopatias congênitas na região Ásia-Pacífico
- Em junho de 2025, a Medtronic anunciou o lançamento na Índia dos Micra AV2 e VR2, os menores marcapassos sem eletrodos do mundo. Projetados para durar mais, funcionar melhor e facilitar a vida de pacientes com ritmos cardíacos lentos, os Micra AV2 e VR2 são as mais recentes inovações da família de marcapassos sem eletrodos Micra da Medtronic. Por não possuírem eletrodos nem exigirem incisão no tórax, ajudam a evitar possíveis complicações, como infecções, que podem ocorrer com marcapassos tradicionais com eletrodos.
- Em setembro de 2024, a Medtronic plc expande as capacidades do Medtronic Customer eXperience Center (MCXC) em Singapura com a inauguração de seu primeiro Robotics Experience Studio no Sudeste Asiático. Isso reforça o compromisso da Medtronic em aprimorar o acesso a novas tecnologias por meio de colaboração, treinamento e educação dentro do ecossistema de saúde.
- Em dezembro de 2025, a FDA aprovou o sistema de substituição da válvula mitral SAPIEN M3 da Edwards Lifesciences como a primeira terapia transcateter transseptal.
- Em outubro de 2025, a Abbott anunciou o lançamento do sistema de marca-passo AVEIR de câmara dupla (DR), o primeiro do gênero no mundo. Este minúsculo dispositivo de alta tecnologia é implantado por meio de um procedimento minimamente invasivo diretamente dentro do coração para ajudá-lo a bater corretamente, sem fios (eletrodos) ou bolsas cirúrgicas utilizadas em marca-passos tradicionais.
- Em agosto de 2025, a Boston iniciou o ensaio clínico AGENT DCB STANCE para comparar diretamente seu balão revestido com medicamento (DCB) Agent com o tratamento padrão de intervenção coronária percutânea (ICP) usando stents farmacológicos ou angioplastia com balão em pacientes com lesões coronárias de novo.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC CONGENITAL HEART DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 COST ANALYSIS BREAKDOWN
4.3.1 INTRODUCTION
4.3.2 CONGENITAL HEART DISEASE COST STRUCTURE OVERVIEW
4.3.2.1 DIAGNOSTIC & IMAGING COST BREAKDOWN
4.3.2.2 SURGICAL TREATMENT COST BREAKDOWN
4.3.2.3 INTERVENTIONAL TREATMENT COST BREAKDOWN
4.3.2.4 HOSPITALIZATION & PROCEDURE COSTS
4.3.2.5 MEDICATION & LONG-TERM CARE COSTS
4.3.3 COST BREAKDOWN BY HOSPITAL TIER
4.3.4 REGIONAL COST VARIATION
4.3.5 MARKET IMPLICATIONS
4.3.6 CONCLUSION
4.4 INDUSTRY INSIGHTS
4.4.1 MICRO AND MACRO ECONOMIC FACTORS
4.4.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.4.3 INTERVIEWS WITH SPECIALISTS
4.4.4 ANALYSIS AND RECOMMENDATION
4.5 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.5.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.5.1.1 JOINT VENTURES
4.5.1.2 MERGERS AND ACQUISITIONS
4.5.1.3 LICENSING AND PARTNERSHIP
4.5.1.4 TECHNOLOGY COLLABORATIONS
4.5.1.5 STRATEGIC DIVESTMENTS.
4.5.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.5.3 STAGE OF DEVELOPMENT
4.5.4 TIMELINES AND MILESTONES
4.5.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.5.6 RISK ASSESSMENT AND MITIGATION
4.5.7 FUTURE OUTLOOK
4.6 NUMBERS OF CONGENITAL HEART DISEASE PATIENT IN EACH COUNTRY
4.7 PATENT ANALYSIS
4.7.1 PATENT QUALITY AND STRENGTH
4.7.2 COUNTRY PATENT LANDSCAPE
4.7.3 IP STRATEGY AND MANAGEMENT
4.7.4 LICENSING AND COLLABORATION
4.8 PREMIUM CLINICAL & COMMERCIAL INSIGHTS:
4.8.1 PATIENT ACCESS
4.8.2 PATIENT DIAGNOSE SITUATION
4.8.3 OPERATION NUMBERS OF CHD PATIENTS
4.8.4 OPERATION NUMBERS OF THE TOP TIER HOSPITAL
4.8.5 TOP SURGEON NAMES
4.8.6 PRODUCT PRICING (AVERAGE SELLING PRICE IN USD)
4.8.6.1 DIAGNOSTIC & IMAGING SYSTEMS
4.8.6.2 SURGICAL DEVICES
4.8.6.3 INTERVENTIONAL DEVICES
4.8.6.4 MEDICATION
4.9 TECHNOLOGY ROADMAP
4.9.1 INTRODUCTION
4.9.2 CURRENT TECHNOLOGY LANDSCAPE (2024–2026)
4.9.2.1 SURGICAL TECHNOLOGIES
4.9.2.2 INTERVENTIONAL DEVICES
4.9.2.3 SUPPORTIVE AND MONITORING TECHNOLOGIES
4.9.2.4 DIGITAL AND DATA-DRIVEN TOOLS
4.9.3 EMERGING TECHNOLOGIES (2026–2030)
4.9.4 FUTURE TECHNOLOGY TRAJECTORY (2030+)
4.9.5 STRATEGIC TAKEAWAYS FOR STAKEHOLDERS
4.9.6 CONCLUSION
4.1 REIMBURSEMENT FRAMEWORK
4.10.1 REIMBURSEMENT STRUCTURES ACROSS ASIA PACIFIC
4.10.2 ROLE OF PUBLIC INSURANCE AND NATIONAL HEALTH POLICIES
4.10.3 PRIVATE INSURANCE AND OUT-OF-POCKET FINANCING
4.10.4 HEALTH TECHNOLOGY ASSESSMENT AND VALUE-BASED REIMBURSEMENT
4.10.5 CHALLENGES IN REIMBURSEMENT FOR CONGENITAL HEART DISEASE CARE
4.10.6 STRATEGIC CONSIDERATIONS FOR MARKET PARTICIPANTS
4.11 OPPORTUNITY MAP ANALYSIS
4.11.1 EXPANSION OF UNIVERSAL HEALTH COVERAGE AND PUBLIC FINANCING
4.11.2 INTEGRATION OF HEALTH TECHNOLOGY ASSESSMENT INTO REIMBURSEMENT
4.11.3 PUBLIC-PRIVATE PARTNERSHIPS TO MITIGATE FINANCIAL BARRIERS
4.11.4 ADDRESSING FRAGMENTATION IN DIGITAL HEALTH REIMBURSEMENT
4.11.5 STRATEGIC ALIGNMENT WITH VALUE-BASED CARE MODELS
4.11.6 STRENGTHENING EQUITABLE ACCESS ACROSS GEOGRAPHIC AND SOCIOECONOMIC LINES
4.11.7 BUILDING CAPACITY FOR REIMBURSEMENT POLICY DEVELOPMENT
4.11.8 CONCLUSION
4.12 SUPPLY CHAIN ECOSYSTEM
4.12.1 PROMINENT COMPANIES
4.12.2 SMALL & MEDIUM SIZE COMPANIES
4.12.3 END USERS
4.13 HEALTHCARE ECONOMY
4.13.1 HEALTHCARE EXPENDITURE
4.13.2 CAPITAL EXPENDITURE
4.13.3 CAPEX TRENDS
4.13.4 CAPEX ALLOCATION
4.13.5 FUNDING SOURCES
4.13.6 INDUSTRY BENCHMARKS
4.13.7 HEALTHCARE EXPENDITURE AS A PROPORTION OF GDP
4.13.8 HEALTHCARE SYSTEM STRUCTURE
4.13.8.1 PUBLIC AND PRIVATE SECTOR COMPOSITION
4.13.8.2 PRIMARY, SECONDARY, AND TERTIARY CARE STRUCTURE
4.13.8.3 REFERRAL AND CARE PATHWAYS
4.13.8.4 REGIONAL DISPARITIES
4.13.8.5 INTEGRATION OF DIGITAL AND TELEHEALTH SERVICES
4.13.8.6 IMPLICATIONS FOR THE CHD MARKET
4.13.9 GOVERNMENT POLICIES
4.13.9.1 HEALTH FINANCING AND REIMBURSEMENT POLICIES
4.13.9.2 REGULATORY AND LICENSING POLICIES
4.13.9.3 NATIONAL HEALTH PROGRAMS AND INITIATIVES
4.13.9.4 TECHNOLOGY ADOPTION AND DIGITAL HEALTH POLICIES
4.13.9.5 IMPLICATIONS FOR THE CHD MARKET
4.13.10 ECONOMIC DEVELOPMENT
4.13.10.1 GDP GROWTH AND HEALTHCARE INVESTMENT
4.13.10.2 INCOME LEVELS AND MARKET SEGMENTATION
4.13.10.3 HUMAN CAPITAL AND SKILLED WORKFORCE
4.13.10.4 INFRASTRUCTURE AND CAPITAL INVESTMENT
4.13.10.5 POLICY IMPLICATIONS AND ECONOMIC PLANNING
4.13.10.6 IMPLICATIONS FOR THE ASIA PACIFIC CHD MARKET
5 TARIFFS & IMPACT ON THE MARKET
5.1 CURRENT TARIFF RATE(S) IN TOP-5 COUNTRY MARKETS
5.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE
5.3 VENDOR SELECTION CRITERIA DYNAMICS
5.4 IMPACT ON SUPPLY CHAIN
5.4.1 RAW MATERIAL PROCUREMENT
5.4.2 MANUFACTURING AND PRODUCTION
5.4.3 LOGISTICS AND DISTRIBUTION
5.4.4 PRICE PITCHING AND POSITION OF MARKET
5.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES
5.5.1 SUPPLY CHAIN OPTIMIZATION
5.5.2 JOINT VENTURE ESTABLISHMENTS
5.6 IMPACT ON PRICES
6 REGULATORY COMPLIANCE
6.1 REGULATORY AUTHORITIES
6.2 REGULATORY CLASSIFICATIONS
6.3 REGULATORY SUBMISSIONS
6.3.1 COMPONENTS OF REGULATORY SUBMISSIONS
6.3.2 SUBMISSION PATHWAYS IN KEY APAC MARKETS
6.3.3 EXPEDITED AND SPECIAL SUBMISSION ROUTES
6.3.4 ELECTRONIC SUBMISSIONS AND DIGITAL PLATFORMS
6.3.5 STRATEGIC CONSIDERATIONS FOR MANUFACTURERS
6.4 INTERNATIONAL HARMONIZATION
6.4.1 HARMONIZATION FRAMEWORKS AND GLOBAL REGULATORY FORUMS
6.4.2 REGIONAL CONVERGENCE INITIATIVES IN ASIA PACIFIC
6.4.3 REGULATORY RELIANCE AND MUTUAL RECOGNITION
6.4.4 BENEFITS OF HARMONIZATION TO THE MEDICAL DEVICE INDUSTRY
6.4.5 CHALLENGES AND ONGOING ADVANCES
6.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
6.6 REGULATORY CHALLENGES AND STRATEGIES
6.6.1 REGULATORY CHALLENGES
6.6.2 REGULATORY STRATEGIES FOR MARKET ACCESS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF CONGENITAL HEART DEFECTS IN NEWBORNS
7.1.2 TECHNOLOGICAL ADOPTION IN INTERVENTIONAL CARDIOLOGY AND DEVICE THERAPY
7.1.3 INCREASING AWARENESS AND EARLY DIAGNOSIS INITIATIVES
7.1.4 GROWTH IN HEALTHCARE INFRASTRUCTURE AND SPECIALIZED PAEDIATRIC CARDIAC UNITS
7.2 RESTRAINTS
7.2.1 HIGH COST FOR THE TREATMENT OF CONGENITAL HEART DISEASE
7.2.2 LIMITED ACCESS TO ADVANCED HEALTHCARE INFRASTRUCTURE
7.3 OPPORTUNITIES
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE IN IMAGING INTERPRETATION AND RISK STRATIFICATION
7.3.2 SCALE-UP OF MINIMALLY INVASIVE TRANSCATHETER THERAPIES
7.3.3 INCREASED GOVERNMENT FUNDING AND PUBLIC-PRIVATE PARTNERSHIPS
7.4 CHALLENGES
7.4.1 SHORTAGE OF SKILLED PEDIATRIC CARDIOLOGISTS
7.4.2 REGULATORY HETEROGENEITY ACROSS ASIA-PACIFIC MARKETS
8 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
8.1 OVERVIEW
8.2 TREATMENT
8.3 DIAGNOSTIC
8.4 ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.4.1 INTERVENTIONAL DEVICES
8.4.2 SUPPORTIVE DEVICES
8.4.3 SURGICAL DEVICES
8.4.4 MEDICATION
8.4.5 OTHERS
8.5 ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.5.1 SEPTAL OCCLUDERS
8.5.2 DELIVERY SYSTEMS
8.5.3 BALLOON CATHETERS
8.5.4 STENTS
8.6 ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.6.1 ASD (ATRIAL SEPTAL DEFECT) OCCLUDERS
8.6.2 VSD (VENTRICULAR SEPTAL DEFECT) OCCLUDERS
8.7 ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.7.1 DRUG-ELUTING STENTS
8.7.2 BARE-METAL STENTS
8.8 ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.8.1 MONITORING SYSTEMS
8.8.2 INFUSION PUMPS
8.9 ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.9.1 PEDIATRIC HEART VALVES
8.9.2 PEDIATRIC VENTRICULAR ASSIST DEVICES
8.9.3 GRAFTS & PATCHES
8.9.4 PEDIATRIC PACEMAKERS
8.9.5 DEFIBRILLATORS
8.1 ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.10.1 BIOPROSTHETIC VALVES
8.10.2 MECHANICAL VALVES
8.11 ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.11.1 ACE INHIBITORS
8.11.2 DIURETICS
8.11.3 BETA BLOCKERS
8.11.4 ANTICOAGULANTS
8.11.5 PROSTAGLANDIN ANALOGS
8.11.6 OTHERS
8.12 ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
8.12.1 CARDIAC CATHETERIZATION LAB EQUIPMENT
8.12.2 ECHOCARDIOGRAPHY SYSTEMS
8.12.3 MRI SYSTEMS
8.12.4 X-RAY DEVICES
8.12.5 CT SCAN SYSTEMS
8.12.6 ELECTROCARDIOGRAPHY (ECG) DEVICES
8.13 ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.13.1 ANGIOGRAPHY SYSTEMS
8.13.2 PRESSURE MONITORS
8.14 ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.14.1 TRANSTHORACIC ECHOCARDIOGRAPHY
8.14.2 TRANSESOPHAGEAL ECHOCARDIOGRAPHY
8.14.3 FETAL ECHOCARDIOGRAPHY
8.15 ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.15.1 CARDIAC MRI
8.15.2 WHOLE-BODY MRI
8.16 ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.16.1 CARDIAC CT
8.16.2 ELECTRON BEAM CT
8.17 ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.17.1 RESTING ECG
8.17.2 STRESS ECG
9 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE, 2018-2033 (USD THOUSANDS)
9.1 OVERVIEW
9.1.1 ACYANOTIC CONGENITAL HEART DISEASE
9.1.2 CYANOTIC CONGENITAL HEART DISEASE
9.1.3 COMPLEX CONGENITAL HEART DEFECTS
9.2 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
9.2.1 VENTRICULAR SEPTAL DEFECT (VSD)
9.2.2 ATRIAL SEPTAL DEFECT (ASD)
9.2.3 PULMONARY STENOSIS
9.2.4 PATENT DUCTUS ARTERIOSUS (PDA)
9.2.5 AORTIC STENOSIS
9.3 ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.3.1 MEMBRANOUS VSD
9.3.2 MUSCULAR VSD
9.4 ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.4.1 OSTIUM SECUNDUM ASD
9.4.2 OSTIUM PRIMUM ASD
9.5 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
9.5.1 TREATMENT
9.5.2 DIAGNOSTIC
9.6 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
9.6.1 TRANSPOSITION OF GREAT ARTERIES
9.6.2 TETRALOGY OF FALLOT
9.6.3 HYPOPLASTIC LEFT HEART SYNDROME
9.6.4 TRICUSPID ATRESIA
9.7 ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.7.1 PULMONARY ATRESIA
9.7.2 OVERRIDING AORTA
9.7.3 RIGHT VENTRICULAR HYPERTROPHY
9.8 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
9.8.1 TREATMENT
9.8.2 DIAGNOSTIC
9.9 ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
9.9.1 TREATMENT
9.9.2 DIAGNOSTIC
10 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSANDS)
10.1 OVERVIEW
10.1.1 ADULTS WITH CONGENITAL HEART DISEASE
10.1.2 NEONATES AND INFANTS (0–1 YEARS)
10.1.3 CHILDREN (1–12 YEARS)
10.1.4 ADOLESCENTS (13–18 YEARS)
11 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSANDS)
11.1 OVERVIEW
11.2 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
11.2.1 HOSPITALS
11.2.2 PEDIATRIC CARDIAC CENTERS
11.2.3 SPECIALTY CLINICS
11.2.4 DIAGNOSTIC LABORATORIES
11.2.5 RESEARCH & ACADEMIC INSTITUTES
11.2.6 HOMECARE SETTINGS
11.2.7 OTHER END USERS
11.3 ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
11.3.1 PUBLIC
11.3.2 PRIVATE
12 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSANDS)
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 WHOLESALE DISTRIBUTORS
12.4 RETAIL SALES
12.5 ONLINE SALES
12.6 OTHERS
13 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET BY COUNTRIES
13.1 ASIA PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 INDIA
13.1.4 SOUTH KOREA
13.1.5 AUSTRALIA
13.1.6 INDONESIA
13.1.7 THAILAND
13.1.8 TAIWAN
13.1.9 VIETNAM
13.1.10 MALAYSIA
13.1.11 SINGAPORE
13.1.12 PHILIPPINES
13.1.13 NEW ZEALAND
13.1.14 REST OF ASIA-PACIFIC
14 ASIA PACIFIC CONGENITAL HEAR DISEASE MARKET
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 MEDICAL DEVICE COMPANY PROFILE
16.1 MEDTRONIC
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 EDWARDS LIFESCIENCES CORPORATION
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 TRIVITRON HEALTHCARE
16.3.1 COMPANY SNAPSHOT
16.3.2 PRODUCT PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 ARTIVION, INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 BOSTON SCIENTIFIC CORPORATION
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 TERUMO CORPORATION
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 SHANGHAI MICROPORT SCIENTIFIC CORPORATION
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 LIFETECH SCIENTIFIC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 LEPU MEDICAL TECHNOLOGY
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 W. L. GORE & ASSOCIATES INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 MERIL
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 LIVANOVA PLC
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT/SERVICE PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 B. BRAUN SE
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT/SERVICE PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 SIEMENS HEALTHINEERS AG
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT/SERVICE PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 KONINKLIJKE PHILIPS N.V.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT/SERVICE PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 GE HEALTHCARE
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT/SERVICE PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 GETINGE AB
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 INTEGER HOLDINGS CORPORATION (PARENT COMPANY OF OSCOR INC.)
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 NARANG MEDICAL LIMITED
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENT
17 PHARMA COMPANY PROFILE
17.1 NOVARTIS AG
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 PFIZER INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENT
17.3 ASTRAZENECA PLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 BRISTOL-MYERS SQUIBB (BMS)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ADVACARE PHARMA
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 29 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 58 CHINA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 59 CHINA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 60 CHINA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 61 CHINA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 CHINA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 63 CHINA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 64 CHINA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 65 CHINA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 CHINA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 67 CHINA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 68 CHINA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 69 CHINA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 70 CHINA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 71 CHINA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 72 CHINA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 73 CHINA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 74 CHINA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 75 CHINA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 76 CHINA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 77 CHINA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 78 CHINA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 79 CHINA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 CHINA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 81 CHINA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 82 CHINA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 83 CHINA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 84 CHINA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 85 CHINA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 86 JAPAN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 87 JAPAN TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 88 JAPAN INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 89 JAPAN SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 90 JAPAN STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 91 JAPAN SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 JAPAN SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 93 JAPAN PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 94 JAPAN MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 95 JAPAN DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 96 JAPAN CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 97 JAPAN ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 98 JAPAN MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 99 JAPAN CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 100 JAPAN ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 JAPAN CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 102 JAPAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 103 JAPAN VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 104 JAPAN ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 105 JAPAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 106 JAPAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 107 JAPAN TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 JAPAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 109 JAPAN COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 110 JAPAN CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 111 JAPAN CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 112 JAPAN HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 JAPAN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 INDIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 INDIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 INDIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 117 INDIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 118 INDIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 119 INDIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 120 INDIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 121 INDIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 122 INDIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 123 INDIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 124 INDIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 125 INDIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 126 INDIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 127 INDIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 128 INDIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 129 INDIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 130 INDIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 131 INDIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 132 INDIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 133 INDIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 134 INDIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 135 INDIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 136 INDIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 137 INDIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 138 INDIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 139 INDIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 140 INDIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 141 INDIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 142 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 143 SOUTH KOREA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 144 SOUTH KOREA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 SOUTH KOREA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 146 SOUTH KOREA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 SOUTH KOREA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 148 SOUTH KOREA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 149 SOUTH KOREA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 150 SOUTH KOREA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 151 SOUTH KOREA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 152 SOUTH KOREA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 153 SOUTH KOREA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 SOUTH KOREA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 SOUTH KOREA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 156 SOUTH KOREA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 158 SOUTH KOREA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 159 SOUTH KOREA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 SOUTH KOREA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 161 SOUTH KOREA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 162 SOUTH KOREA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 163 SOUTH KOREA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 SOUTH KOREA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 165 SOUTH KOREA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 166 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 167 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 168 SOUTH KOREA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 169 SOUTH KOREA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 171 AUSTRALIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 172 AUSTRALIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 AUSTRALIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 174 AUSTRALIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 175 AUSTRALIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 176 AUSTRALIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 AUSTRALIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 178 AUSTRALIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 179 AUSTRALIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 AUSTRALIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 AUSTRALIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 182 AUSTRALIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 183 AUSTRALIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 AUSTRALIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 185 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 186 AUSTRALIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 187 AUSTRALIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 188 AUSTRALIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 189 AUSTRALIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 190 AUSTRALIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 191 AUSTRALIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 192 AUSTRALIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 193 AUSTRALIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 194 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 195 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 196 AUSTRALIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 AUSTRALIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 198 INDONESIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 199 INDONESIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 INDONESIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 INDONESIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 202 INDONESIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 203 INDONESIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 204 INDONESIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 INDONESIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 206 INDONESIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 207 INDONESIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 208 INDONESIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 209 INDONESIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 210 INDONESIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 211 INDONESIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 INDONESIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 213 INDONESIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 214 INDONESIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 215 INDONESIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 216 INDONESIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 217 INDONESIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 218 INDONESIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 219 INDONESIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 220 INDONESIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 221 INDONESIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 222 INDONESIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 223 INDONESIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 224 INDONESIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 225 INDONESIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 THAILAND CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 227 THAILAND TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 228 THAILAND INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 THAILAND SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 230 THAILAND STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 231 THAILAND SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 232 THAILAND SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 THAILAND PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 234 THAILAND MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 235 THAILAND DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 236 THAILAND CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 237 THAILAND ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 238 THAILAND MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 239 THAILAND CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 240 THAILAND ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 241 THAILAND CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 242 THAILAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 243 THAILAND VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 244 THAILAND ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 THAILAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 246 THAILAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 247 THAILAND TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 THAILAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 249 THAILAND COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 250 THAILAND CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 251 THAILAND CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 252 THAILAND HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 253 THAILAND CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 254 TAIWAN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 255 TAIWAN TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 256 TAIWAN INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 257 TAIWAN SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 258 TAIWAN STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 259 TAIWAN SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 260 TAIWAN SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 261 TAIWAN PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 262 TAIWAN MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 263 TAIWAN DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 264 TAIWAN CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 265 TAIWAN ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 266 TAIWAN MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 267 TAIWAN CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 268 TAIWAN ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 269 TAIWAN CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 270 TAIWAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 271 TAIWAN VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 272 TAIWAN ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 273 TAIWAN ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 274 TAIWAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 275 TAIWAN TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 276 TAIWAN CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 277 TAIWAN COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 278 TAIWAN CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 279 TAIWAN CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 280 TAIWAN HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 281 TAIWAN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 282 VIETNAM CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 283 VIETNAM TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 284 VIETNAM INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 285 VIETNAM SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 286 VIETNAM STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 287 VIETNAM SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 288 VIETNAM SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 289 VIETNAM PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 290 VIETNAM MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 291 VIETNAM DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 292 VIETNAM CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 293 VIETNAM ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 294 VIETNAM MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 295 VIETNAM CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 296 VIETNAM ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 297 VIETNAM CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 298 VIETNAM ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 299 VIETNAM VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 300 VIETNAM ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 301 VIETNAM ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 302 VIETNAM CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 303 VIETNAM TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 304 VIETNAM CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 305 VIETNAM COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 306 VIETNAM CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 307 VIETNAM CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 308 VIETNAM HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 309 VIETNAM CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 310 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 311 MALAYSIA TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 312 MALAYSIA INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 313 MALAYSIA SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 314 MALAYSIA STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 315 MALAYSIA SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 316 MALAYSIA SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 317 MALAYSIA PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 318 MALAYSIA MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 319 MALAYSIA DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 320 MALAYSIA CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 321 MALAYSIA ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 322 MALAYSIA MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 323 MALAYSIA CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 324 MALAYSIA ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 325 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 326 MALAYSIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 327 MALAYSIA VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 328 MALAYSIA ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 329 MALAYSIA ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 330 MALAYSIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 331 MALAYSIA TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 332 MALAYSIA CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 333 MALAYSIA COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 334 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 335 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 336 MALAYSIA HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 337 MALAYSIA CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 338 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 339 SINGAPORE TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 340 SINGAPORE INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 341 SINGAPORE SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 342 SINGAPORE STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 343 SINGAPORE SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 344 SINGAPORE SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 345 SINGAPORE PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 346 SINGAPORE MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 347 SINGAPORE DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 348 SINGAPORE CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 349 SINGAPORE ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 350 SINGAPORE MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 351 SINGAPORE CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 352 SINGAPORE ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 353 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 354 SINGAPORE ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 355 SINGAPORE VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 356 SINGAPORE ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 357 SINGAPORE ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 358 SINGAPORE CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 359 SINGAPORE TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 360 SINGAPORE CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 361 SINGAPORE COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 362 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 363 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 364 SINGAPORE HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 365 SINGAPORE CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 366 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 367 PHILIPPINES TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 368 PHILIPPINES INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 369 PHILIPPINES SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 370 PHILIPPINES STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 371 PHILIPPINES SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 372 PHILIPPINES SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 373 PHILIPPINES PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 374 PHILIPPINES MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 375 PHILIPPINES DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 376 PHILIPPINES CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 377 PHILIPPINES ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 378 PHILIPPINES MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 379 PHILIPPINES CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 380 PHILIPPINES ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 381 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 382 PHILIPPINES ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 383 PHILIPPINES VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 384 PHILIPPINES ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 385 PHILIPPINES ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 386 PHILIPPINES CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 387 PHILIPPINES TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 388 PHILIPPINES CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 389 PHILIPPINES COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 390 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 391 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 392 PHILIPPINES HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 393 PHILIPPINES CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 394 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 395 NEW ZEALAND TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 396 NEW ZEALAND INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 397 NEW ZEALAND SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 398 NEW ZEALAND STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 399 NEW ZEALAND SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 400 NEW ZEALAND SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 401 NEW ZEALAND PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 402 NEW ZEALAND MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 403 NEW ZEALAND DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 404 NEW ZEALAND CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 405 NEW ZEALAND ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 406 NEW ZEALAND MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 407 NEW ZEALAND CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 408 NEW ZEALAND ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 409 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 410 NEW ZEALAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 411 NEW ZEALAND VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 412 NEW ZEALAND ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 413 NEW ZEALAND ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 414 NEW ZEALAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 415 NEW ZEALAND TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 416 NEW ZEALAND CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 417 NEW ZEALAND COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 418 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 419 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 420 NEW ZEALAND HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 421 NEW ZEALAND CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 422 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 423 REST OF ASIA-PACIFIC TREATMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 424 REST OF ASIA-PACIFIC INTERVENTIONAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 425 REST OF ASIA-PACIFIC SEPTAL OCCLUDERS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 426 REST OF ASIA-PACIFIC STENTS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 427 REST OF ASIA-PACIFIC SUPPORTIVE DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 428 REST OF ASIA-PACIFIC SURGICAL DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 429 REST OF ASIA-PACIFIC PEDIATRIC HEART VALVES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 430 REST OF ASIA-PACIFIC MEDICATION IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 431 REST OF ASIA-PACIFIC DIAGNOSTIC IN CONGENITAL HEART DISEASE MARKET, BY DEVICE TYPE, 2018-2033 (USD THOUSAND)
TABLE 432 REST OF ASIA-PACIFIC CARDIAC CATHETERIZATION LAB EQUIPMENT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 433 REST OF ASIA-PACIFIC ECHOCARDIOGRAPHY SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 434 REST OF ASIA-PACIFIC MRI SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 435 REST OF ASIA-PACIFIC CT SCAN SYSTEMS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 436 REST OF ASIA-PACIFIC ELECTROCARDIOGRAPHY (ECG) DEVICES IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 437 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE , 2018-2033 (USD THOUSAND)
TABLE 438 REST OF ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 439 REST OF ASIA-PACIFIC VENTRICULAR SEPTAL DEFECT (VSD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 440 REST OF ASIA-PACIFIC ATRIAL SEPTAL DEFECT (ASD) IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 441 REST OF ASIA-PACIFIC ACYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 442 REST OF ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY TYPES, 2018-2033 (USD THOUSAND)
TABLE 443 REST OF ASIA-PACIFIC TETRALOGY OF FALLOT IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 444 REST OF ASIA-PACIFIC CYANOTIC CONGENITAL HEART DISEASE IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 445 REST OF ASIA-PACIFIC COMPLEX CONGENITAL HEART DEFECTS IN CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE , 2018-2033 (USD THOUSAND)
TABLE 446 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2018-2033 (USD THOUSAND)
TABLE 447 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER , 2018-2033 (USD THOUSAND)
TABLE 448 REST OF ASIA-PACIFIC HOSPITALS IN CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 449 REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
Lista de Figura
FIGURE 1 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: MULTIVARIATE MODELLING
FIGURE 8 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: SEGMENTATION
FIGURE 12 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: EXECUTIVE SUMMARY
FIGURE 13 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: STRATEGIC DECISIONS
FIGURE 14 TWO SEGMENTS COMPRISE THE DOMINICAN REPUBLIC ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
FIGURE 15 RISING PREVALENCE OF CONGENITAL HEART DEFECTS IN NEWBORNS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC CONGENITAL HEART DISEASE MARKET FROM 2026 TO 2033
FIGURE 16 THE TYPE 2 ENDOSCOPIC HEMOSTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC CONGENITAL HEART DISEASE MARKET IN 2026 & 2033
FIGURE 17 DROC ANALYSIS
FIGURE 18 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY PRODUCT TYPE, 2025
FIGURE 19 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY PRODUCT TYPE, 2026-2033 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY PRODUCT TYPE, CAGR (2026-2033)
FIGURE 21 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISEASE TYPE, 2025
FIGURE 23 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISEASE TYPE, 2026-2033 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISEASE TYPE, CAGR (2026-2033)
FIGURE 25 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY AGE GROUP, 2025
FIGURE 27 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY AGE GROUP, 2026-2033 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY AGE GROUP, CAGR (2026-2033)
FIGURE 29 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY END USER, 2025
FIGURE 31 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY END USER, CAGR (2026-2033)
FIGURE 33 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2025
FIGURE 35 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 36 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026-2033)
FIGURE 37 ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET SNAPSHOTS
FIGURE 39 ASIA PACIFIC CONGENITAL HEART DISEASE MARKET: COMPANY SHARE 2025 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
